Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Beneish M-Score: -2.85 (As of Jun. 27, 2026)


SHSE:600276 Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
86 GF Score
Price ¥48.67
GF Value ¥60.34
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co Beneish M-Score?

Jiangsu Hengrui Pharmaceuticals Co SHSE:600276 -2.74% 86 Beneish M-Score is -2.85 as of Jun. 27, 2026. GuruFocus rates SHSE:600276 with a GF Score™ of 86/100 and a GF Value™ of ¥60.34 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 911 Drug Manufacturers companies, Jiangsu Hengrui Pharmaceuticals Co ranks better than 78.49% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.85 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score or its related term are showing as below:

SHSE:600276' s Beneish M-Score Range Over the Past 10 Years
Min: -3.18   Med: -2.22   Max: -1.25
Current: -2.85

During the past 13 years, the highest Beneish M-Score of Jiangsu Hengrui Pharmaceuticals Co was -1.25. The lowest was -3.18. And the median was -2.22.


Jiangsu Hengrui Pharmaceuticals Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Hengrui Pharmaceuticals Co Beneish M-Score Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.42 -1.69 -2.88 -2.59 -2.83

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.32 -2.53 -3.00 -2.83 -2.85

SHSE:600276 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score falls into.


SHSE:600276
86GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Hengrui Pharmaceuticals Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Jiangsu Hengrui Pharmaceuticals Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7948+0.528 * 0.9983+0.404 * 0.9712+0.892 * 1.1155+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9188+4.679 * -0.046952-0.327 * 1.1916
=-2.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥6,507 Mil.
Revenue was 8140.565 + 8441.334 + 7426.888 + 8555.583 = ¥32,564 Mil.
Gross Profit was 7049.616 + 7274.12 + 6346.409 + 7509.283 = ¥28,179 Mil.
Total Current Assets was ¥52,044 Mil.
Total Assets was ¥71,294 Mil.
Property, Plant and Equipment(Net PPE) was ¥8,128 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥7,619 Mil.
Total Current Liabilities was ¥5,637 Mil.
Long-Term Debt & Capital Lease Obligation was ¥37 Mil.
Net Income was 2282.268 + 1959.885 + 1301.063 + 2576.051 = ¥8,119 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 786.446 + 2124.948 + 4809.977 + 3745.279 = ¥11,467 Mil.
Total Receivables was ¥7,339 Mil.
Revenue was 7205.611 + 7795.301 + 6588.57 + 7603.2 = ¥29,193 Mil.
Gross Profit was 6136.949 + 6780.307 + 5628.691 + 6672.746 = ¥25,219 Mil.
Total Current Assets was ¥35,970 Mil.
Total Assets was ¥51,293 Mil.
Property, Plant and Equipment(Net PPE) was ¥7,085 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥7,433 Mil.
Total Current Liabilities was ¥3,363 Mil.
Long-Term Debt & Capital Lease Obligation was ¥63 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(6507.29 / 32564.37) / (7339.448 / 29192.682)
=0.199829 / 0.251414
=0.7948

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(25218.693 / 29192.682) / (28179.428 / 32564.37)
=0.86387 / 0.865345
=0.9983

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (52044.195 + 8128.268) / 71293.862) / (1 - (35969.766 + 7084.618) / 51292.782)
=0.155994 / 0.160615
=0.9712

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=32564.37 / 29192.682
=1.1155

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 7084.618)) / (0 / (0 + 8128.268))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(7618.869 / 32564.37) / (7433.388 / 29192.682)
=0.233963 / 0.254632
=0.9188

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((37.103 + 5636.724) / 71293.862) / ((62.712 + 3362.881) / 51292.782)
=0.079584 / 0.066785
=1.1916

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(8119.267 - 0 - 11466.65) / 71293.862
=-0.046952

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Jiangsu Hengrui Pharmaceuticals Co has a M-score of -2.85 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.85 mean?
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Beneish M-Score of -2.85 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #196 out of 911 companies in the Drug Manufacturers industry, placing it in the top 21.5%.
Is Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score too high?
Jiangsu Hengrui Pharmaceuticals Co's current Beneish M-Score is -2.85. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #196 out of 911 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #196 out of 911 companies for Beneish M-Score. This places Jiangsu Hengrui Pharmaceuticals Co in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. Jiangsu Hengrui Pharmaceuticals Co's current Beneish M-Score is -2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.34, compared to a current price of ¥48.67 — trading 19.3% below its estimated fair value. The current Beneish M-Score is -2.85. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Beneish M-Score is -2.85 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued. The current stock price of ¥48.67 is trading 19.3% below its estimated GF Value™ of ¥60.34. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for SHSE:600276:

  • Beneish M-Score: -2.85
  • GF Value™: ¥60.34 vs. price of ¥48.67 (19.3% below fair value)
  • GF Score™: 86/100 with 1 warning sign

No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
86GF Score

Get the complete analysis for SHSE:600276

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥48.67
Price
¥60.34
GF Value